[Cerebral phospholipids and Parkinson's disease: cross-over double-blind study versus placebo].
Authors refer in this study their clinical experience with brain cortex phospholipids (BC-PL) in patients affected by Parkinson's disease and treated with L-DOPA plus IDD. It's plain from results elaborated through statistical examinations a positive influence more on motor timing performances (screw-test, gait-test, peg-board test) than each item of Webster rating scale. Moreover getting in connection high nervous functions with motor activity, authors suppose BC-PL have a primary and direct action on cortical cholinergic structures correlated with attention, learning and memory and consequently a secondary action on motor performances.
D000818:Animals; D001921:Brain; D002417:Cattle; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010743:Phospholipids / Q000627:therapeutic use*; D010919:Placebos; D014020:Tissue Extracts / Q000627:therapeutic use*
D010743:Phospholipids; D010919:Placebos; D014020:Tissue Extracts
Fosfolipidi cerebrali e morbo di Parkinson: studio in doppio cieco cross-over versus placebo.